Minicircle
Minicircle is a US-based private gene therapy company that administers non-viral plasmid therapies (Follistatin, with Klotho launching in 2026) through international clinic partners in Honduras, the Bahamas, and Panama, serving affluent longevity enthusiasts and biohackers seeking FDA-cleared alternatives.
- Company typePrivate
- Founded2019
- HeadquartersLos Angeles, United States
- Headcount11–50
- GTM typeB2C
- OfferingServices
What Minicircle does
Minicircle is a private US-based gene therapy company developing a non-viral plasmid platform targeting human longevity, anti-aging, and performance enhancement. The company currently offers Follistatin, a plasmid gene therapy administered via subcutaneous injection that is reported to support lean muscle growth, reduce body fat, and lower epigenetic age, with effects described as non-heritable and lasting approximately one year. A second product, Klotho, is in development with anticipated release at overseas clinics in 2026. All therapies are investigational, have not been reviewed by the FDA, and are administered by licensed clinicians at independent international partner clinics operating under regulatory frameworks outside the United States.
The business model is consumer-direct, quote-based pricing with patients joining a waitlist via the company website; revenue flows from per-treatment administration rather than subscription or licensing. Distribution is exclusively through partner clinics in jurisdictions with permissive regulatory regimes — specifically Honduras (including the Próspera/Vitalia zone on Roatán), the Bahamas, and Panama — a structure that allows the company to commercialize therapies that have not completed US clinical trials. Go-to-market is concentrated in the biohacking and longevity enthusiast segment, with marketing anchored on testimonials from Bryan Johnson, Ben Greenfield, Kenneth Scott, and a feature in the Netflix documentary "Don't Die: The Man Who Wants to Live Forever."
The company was founded in 2019, operates with 11-50 employees, and is led by founder and CEO Mac Davis. Total disclosed funding is modest, with a 2021 round from Quiet Capital and Sprint VC and a 2024 round of $458,511 from Gaingels. The entity is incorporated in the United States as Minicircle Inc, headquartered in Austin, Texas (with conflicting firmographic data listing Los Angeles). The company has administered 100+ therapies cumulatively and positions itself as a gene therapy platform rather than a medical provider.
Minicircle firmographics
Firmographics- Name
- Minicircle
- Legal name
- Minicircle Inc
- Website
- https://minicircle.org
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Minicircle is a US-based private gene therapy company that administers non-viral plasmid therapies (Follistatin, with Klotho launching in 2026) through international clinic partners in Honduras, the Bahamas, and Panama, serving affluent longevity enthusiasts and biohackers seeking FDA-cleared alternatives.
- Ownership category
- akta.pro rank
Minicircle industry classification
Industry- Product category
- Gene Therapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery) (HLAAACAL)
- akta.pro secondary industry
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
Keywords
Where Minicircle is headquartered
LocationHeadquarters
- HQ city
- Los Angeles
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Minicircle business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Gene Therapy Administration: Minicircle generates revenue by providing plasmid gene therapies (Follistatin currently, Klotho coming 2026) through independent international partner clinics. The therapies are administered via subcutaneous injection at select clinics in Central America.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Gene therapy treatment pricing |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels7 records
Minicircle product offering
Product offeringCore offering
Minicircle is a gene therapy platform that develops and provides non-viral plasmid-based gene therapies for longevity, performance, and wellness. Its current product, Follistatin, is a plasmid gene therapy administered via subcutaneous injection to support lean muscle growth, reduce body fat, and lower epigenetic age. Treatments are delivered through licensed clinicians at independent international partner clinics in Central America (Honduras, Bahamas, Panama) outside US FDA jurisdiction.
Product overview
Minicircle is a gene therapy platform offering plasmid-based gene therapies for longevity, performance, and wellness. The company provides two primary therapeutic products: Follistatin (currently available) and Klotho (launching 2026). Follistatin is a non-viral plasmid gene therapy administered via subcutaneous injection that supports lean muscle growth, reduces body fat, and lowers epigenetic age. Klotho is an anti-aging gene therapy targeting the klotho protein. All therapies are investigational, have not been reviewed by the FDA, and are administered by licensed clinicians at independent international partner clinics operating outside the United States.
Differentiator
Problem solved
Functional benefit
Products and services
- Follistatin Plasmid gene therapy designed to increase follistatin protein production, supporting lean muscle growth, fat reduction, and long-term vitality. Administered via subcutaneous injection, with non-heritable effects lasting approximately 1 year. Clinical trial participants experienced an average 2-pound increase in fat-free mass, 0.87% body fat reduction, and a 12-year reduction in epigenetic age in aged participants. For individual consumers seeking longevity and performance optimization.
Quantifiable outcome
- Clinical trial participants experienced average 2-pound increase in fat-free mass
- +3 more outcomes
Companies that use Minicircle
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles1 record
Minicircle technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Minicircle partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Independent International Clinic PartnerscoreMinicircle partners with licensed clinicians at independent international health clinics operating under regulatory frameworks outside the United States. These clinic partners administer Minicircle's gene therapies (Follistatin, Klotho) to patients. The company explicitly states 'all therapies are administered by licensed clinicians at independent international partner clinics operating under regulatory frameworks outside the United States.'
- Próspera/Vitalia (Honduras)coreMinicircle completed a follistatin gene-therapy study in the Próspera/Vitalia zone on Roatán, Honduras. This private city operates as an autonomous zone under special economic zone laws and has attracted biotech startups and medical tourists seeking gene therapies that face regulatory restrictions elsewhere. Despite legal challenges to ZEDE laws, Minicircle has conducted clinical research in this jurisdiction.
Scale indicators2 records
Recent moves5 records
Expansion highlights5 records
Minicircle competitors and assessment
Company assessmentEmerging players
- Insilico Medicine: AI-driven drug discovery company with a longevity pipeline (including Klotho-related programs). Competes for the same investor and patient attention in longevity biotech and represents a potential strategic acquirer of Minicircle's plasmid platform.
- AgeX Therapeutics: Biotech focused on cellular rejuvenation and induced tissue regeneration (iTR) for aging. Pursues longevity therapeutics through a different modality (pluripotent stem cell-derived treatments) but the same anti-aging target market and scientific framework.
- Elevian: Regenerative medicine biotech developing recombinant GDF11 for age-related diseases. Targets the same longevity/healthy-lifespan customer thesis as Minicircle but pursues FDA-regulated development paths with larger funding.
- Rejuvenate Bio: George Church spin-out using gene therapy (including follistatin) to treat age-related diseases in companion animals and humans. Direct methodological overlap with Minicircle's follistatin therapy and similar gene-therapy-for-aging thesis.
- Unity Biotechnology: Clinical-stage biotech developing senolytic therapies for age-related diseases. Mentioned alongside Minicircle in press coverage of longevity/transhumanist technologies. Pursues the same aging patient market through formal FDA pathways.
- CohBar: Clinical-stage biotech developing mitochondria-derived peptides (MBTs) for age-related diseases including NASH, obesity, and cancer. Competes for the same anti-aging biology platform investment thesis as Minicircle.
- Loyal for Dogs: Biotech developing FDA-conditional longevity drugs for dogs. Operates in the broader animal/human longevity therapeutics category and competes for the same longevity-investor capital and brand narrative as Minicircle.
Direct peers
- Libella Gene Therapeutics: Libella offered gene therapies (including telomerase) for longevity through clinical trials conducted in Colombia to avoid US regulation — a near-identical strategy to Minicircle's Central American clinic model for accessing experimental anti-aging therapies.
- BioViva: BioViva is a direct peer offering experimental gene therapies for aging and longevity, including telomere and follistatin therapies, administered offshore to bypass FDA. Mirrors Minicircle's regulatory-arbitrage, longevity-tourism business model and target customer base.
Others
- Maximum Life Foundation: Non-profit focused on advancing regenerative and gene therapies for human longevity. Operates as ecosystem participant/advisor in the same niche as Minicircle and has publicly backed similar telomere/gene therapy clinical research.
Market position
Strengths3 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Minicircle social profiles
Digital presenceMinicircle financial estimates
Financial estimateRevenue estimate
Valuation estimate
Minicircle leadership team
Management profileNumber of profiles
Profiles1 record
Minicircle funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Minicircle M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Minicircle
What does Minicircle do?
Minicircle is a gene therapy platform that develops and provides non-viral plasmid-based gene therapies for longevity, performance, and wellness. Its current product, Follistatin, is a plasmid gene therapy administered via subcutaneous injection to support lean muscle growth, reduce body fat, and lower epigenetic age. Treatments are delivered through licensed clinicians at independent international partner clinics in Central America (Honduras, Bahamas, Panama) outside US FDA jurisdiction.
Is Minicircle a public or private company?
Minicircle is a private company. It is classified as venture growth investor backed and is currently operating.
When was Minicircle founded?
Minicircle was founded in 2019. It employs 11 to 50 people.
Where is Minicircle based?
Minicircle is headquartered in Los Angeles, United States, in the North America region.
How does Minicircle make money?
One revenue line is on record: gene Therapy Administration.
Who are Minicircle's main competitors?
Emerging players on record are Insilico Medicine, AgeX Therapeutics, Elevian, Rejuvenate Bio, Unity Biotechnology, CohBar and Loyal for Dogs. Direct peers are Libella Gene Therapeutics and BioViva. Maximum Life Foundation is listed as an others.
Does Minicircle have an API?
No public API is recorded for Minicircle.
What industry is Minicircle in?
Minicircle's product category is Gene Therapy. Its primary akta.pro industry code is HLAAACAL, Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 541714 and its SIC code is 2836.